Ona Therapeutics Strengthens Leadership Team to Accelerate First-in-Class ADCs into ...
Ona Therapeutics ("Ona"), a global biotech company pioneering first-in-class antibody-drug conjugates (ADCs), today announced key leadership appointments to support its rapid growth and pipeline ...
BioWorld4 天
Ona advances ADCs for solid tumors toward clinic
Ona Therapeutics SL is accelerating development of its first-in-class antibody-drug conjugate (ADC) therapeutics, targeting novel tumor-specific markers to eliminate hard-to-treat, resistant cancer ...
News Medical5 天
Cancer-free for 18 years: CAR-T therapy sets new milestone in neuroblastoma treatment
A groundbreaking study in Nature Medicine reveals that GD2 CAR-T cell therapy can lead to long-term remission in children ...
PharmiWeb8 天
Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update
Patients Achieved Remission Within 30 Days in Cohort 1 of the Mipletamig RAINIER Dose Optimization Trial for Frontline AML Patients, Trial Enrollment ContinuesPromising Data, including a 59% Stable ...
BioSpace8 天
Amgen, Ideaya Call It Quits on Cancer Combo
Amgen will continue to advance half of the combo, PRMT5 inhibitor AMG 193, for which it is running a mid-stage trial in ...
The Pharma Letter9 天
Korean partners aim to take next step in ADC field
South Korea's DAAN Biotherapeutics has entered an exclusive deal with LigaChem Biosciences to develop a novel tumor-targeting ...
Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development ...
Bolt Biotherapeutics, Inc., announced today that the target of their worldwide co-development collaboration with Toray Industries, Inc. is Caprin-1, a novel cancer target discovered by Toray. The ...
Marker Therapeutics (NASDAQ:MRKR) Stock Price Down 2.8% – What’s Next?
Marker Therapeutics, Inc. (NASDAQ:MRKR – Get Free Report) fell 2.8% during trading on Monday . The stock traded as low as $1.66 and last traded at $1.72. 62,549 shares changed hands during trading, a ...
Brookline Capital sets $4 target on Marker Therapeutics stock
Brookline Capital Markets initiated coverage on Marker Therapeutics (NASDAQ:MRKR), a company focused on developing T cell-based immunotherapies for cancer, with a Buy rating and a 12-to-18-month price ...
Marker Therapeutics initiated with a Buy at Brookline
Brookline initiated coverage of Marker Therapeutics (MRKR) with a Buy rating and $4 price target Marker is a clinical-stage immuno-oncology ...
devdiscourse17 天
New AI model cracks cancer prognostics, outshines traditional methods
Beyond improving accuracy, xAI allowed researchers to compare prognostic markers across different cancer types, unveiling ...
Kaleido Scope18 天
Leavenworth and Markert published in Nature Communications
The study, titled “Oncolytic reprogramming of tumor microenvironment shapes CD4 T-cell memory via the IL6ra-Bcl6 axis for targeted control of glioblastoma,” investigates the impact of an oncolytic ...